Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Sep 13 04:00PM ET
123.40
Dollar change
+18.40
Percentage change
17.52
%
Index- P/E- EPS (ttm)-2.32 Insider Own0.26% Shs Outstand237.73M Perf Week37.20%
Market Cap29.34B Forward P/E- EPS next Y-2.96 Insider Trans0.00% Shs Float237.11M Perf Month45.43%
Income-544.48M PEG- EPS next Q-1.53 Inst Own17.80% Short Float1.09% Perf Quarter28.54%
Sales2.91B P/S10.09 EPS this Y-159.62% Inst Trans12.39% Short Ratio3.53 Perf Half Y32.82%
Book/sh85.98 P/B1.44 EPS next Y-17.01% ROA-2.26% Short Interest2.58M Perf Year8.96%
Cash/sh46.78 P/C2.64 EPS next 5Y- ROE-2.58% 52W Range76.53 - 117.98 Perf YTD16.92%
Dividend Est.- P/FCF9.81 EPS past 5Y- ROI-2.63% 52W High4.59% Beta0.20
Dividend TTM- Quick Ratio7.40 Sales past 5Y843.27% Gross Margin82.90% 52W Low61.24% ATR (14)5.18
Dividend Ex-DateJun 02, 2022 Current Ratio7.54 EPS Y/Y TTM-112.44% Oper. Margin-20.10% RSI (14)87.43 Volatility10.46% 4.81%
Employees3082 Debt/Eq0.01 Sales Y/Y TTM-69.08% Profit Margin-18.73% Recom2.11 Target Price111.38
Option/ShortYes / Yes LT Debt/Eq0.01 EPS Q/Q-323.29% Payout0.00% Rel Volume8.51 Prev Close105.00
Sales Surprise-3.82% EPS Surprise-67.53% Sales Q/Q-24.09% EarningsAug 05 BMO Avg Volume731.05K Price123.40
SMA2035.87% SMA5043.09% SMA20033.22% Trades Volume6,222,014 Change17.52%
Date Action Analyst Rating Change Price Target Change
Aug-07-24Upgrade Deutsche Bank Hold → Buy $95
Aug-02-24Upgrade HSBC Securities Hold → Buy
May-14-24Initiated Evercore ISI In-line $100
Feb-23-24Initiated BMO Capital Markets Outperform $127
Jan-05-24Initiated Oppenheimer Perform
Dec-01-23Downgrade JP Morgan Neutral → Underweight $106 → $99
Oct-16-23Downgrade HSBC Securities Buy → Hold $124 → $111
Jul-14-23Initiated HSBC Securities Buy $124
May-17-23Upgrade Redburn Neutral → Buy $165 → $170
Dec-15-22Upgrade BofA Securities Neutral → Buy $239
Sep-13-24 06:41PM
09:34AM
06:12AM
Sep-05-24 07:15AM
Sep-04-24 09:15AM
08:30AM Loading…
08:30AM
Aug-26-24 06:52AM
Aug-23-24 02:01PM
Aug-22-24 02:33PM
02:15PM
01:44PM
Aug-21-24 12:12AM
Aug-20-24 05:52AM
Aug-19-24 09:39AM
08:05AM
04:07AM Loading…
04:07AM
Aug-16-24 11:12PM
04:21PM
04:08PM
01:29PM
10:21AM
08:20AM
06:45AM
Aug-13-24 02:43PM
Aug-08-24 06:40AM
Aug-05-24 02:30PM
01:24PM
11:53AM
10:28AM
07:59AM
06:02AM Loading…
06:02AM
05:59AM
Jul-30-24 06:52AM
06:45AM
Jul-24-24 06:33AM
Jul-22-24 06:45AM
Jul-02-24 08:00AM
Jul-01-24 11:00PM
12:34PM
12:19PM
Jun-28-24 04:32AM
Jun-27-24 10:30AM
Jun-24-24 06:45AM
Jun-18-24 11:53AM
10:19AM
Jun-17-24 11:50AM
Jun-03-24 03:41PM
09:17AM
04:45AM
Jun-01-24 10:00AM
May-31-24 07:15AM
May-30-24 04:25AM
May-29-24 08:00AM
May-26-24 08:00PM
May-24-24 12:16PM
08:15AM
May-21-24 06:45AM
04:00AM
May-20-24 02:09PM
May-18-24 02:42AM
May-17-24 02:46PM
01:17PM
12:36PM
11:15AM
May-14-24 07:58AM
May-07-24 11:26AM
06:22AM
05:08AM
May-06-24 04:14PM
04:04PM
02:30PM
12:11PM
12:02PM
11:53AM
10:16AM
08:57AM
08:15AM
07:31AM
07:23AM
07:03AM
07:03AM
06:49AM
06:45AM
May-03-24 10:08AM
Apr-30-24 11:58AM
Apr-25-24 01:51PM
01:28PM
12:55PM
11:27AM
09:54AM
09:39AM
Apr-23-24 07:21AM
Apr-22-24 06:08PM
06:45AM
Apr-07-24 02:00PM
Mar-31-24 03:39PM
Mar-26-24 09:53AM
06:44AM
01:00AM
Mar-25-24 06:47AM
BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
ATHOS KG10% OwnerSep 13 '24Proposed Sale115.02170,00019,552,584Sep 13 04:12 PM